EMA Authorised: Ketoconazole Esteve (previously Ketoconazole HRA) (Ketoconazole) — Esteve Pharmaceuticals, S.A.

View source ↗

Summary

The EMA has authorised Ketoconazole Esteve for the treatment of Cushing syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cushing Syndrome

Drugs mentioned

• Ketoconazole Esteve (Ketoconazole)

Snippet

Status: Authorised. Therapeutic area: Cushing Syndrome. MAH: Esteve Pharmaceuticals, S.A.. Decision date: 04/04/2025. Accelerated assessment